Key result
An 8-year-old boy treated with high-dose corticosteroids and intravenous immunoglobulin for MIS-C developed severe hypertension and posterior reversible encephalopathy syndrome.
Why the study?
Medications used to treat multisystem inflammatory syndrome in children, specifically corticosteroids and intravenous immunoglobulin, increase the risk of posterior reversible encephalopathy syndrome (PRES).
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
Treatment of multisystem inflammatory syndrome in children with high-dose corticosteroids and intravenous immunoglobulin can trigger severe hypertension and posterior reversible encephalopathy syndrome (PRES).
An 8-year-old boy admitted for multisystem inflammatory syndrome in children (MIS-C) presents with altered mental status and hypertension on hospital day 8. He has a history of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection 4 weeks earlier. He initially presented to the emergency department with fever for 4 consecutive days, headache, abdominal pain, vomiting, and diarrhea. On physical examination, his vital signs were within normal limits and his BMI was within normal range. He was nontoxic appearing, with bilateral conjunctival injection, cracked lips, and strawberry tongue. His examination was negative for cardiac murmur, rash, edema and erythema of his hands and feet, and lymphadenopathy. His laboratory values on admission demonstrated normocytic anemia (hemoglobin level, 10.9 g/dL [109 g/L] [reference range, 11.5–15.5 g/dL (115–155 g/L)]); elevated cardiac enzyme levels (troponin, 1.35 ng/mL [1.35 µg/L] [<0.045 ng/mL (<0.045 µg/L)]; brain natriuretic peptide level, 248 pg/mL [248 ng/L] [reference range, <100.0 pg/mL (<100.0 ng/L)]); elevated inflammatory markers (C-reactive protein level, 13.8 mg/dL [138 mg/L] [reference range, <1.0 mg/dL (<10 mg/L)]; erythrocyte sedimentation rate, 54 mm/hr [reference range, 0–15 mm/hr]; ferritin level, 194 ng/mL [194 µg/L] [reference range, 13.7–78.8 ng/mL (13.7–78.8 µg/L)]); hypoalbuminemia (albumin level, 2.9 g/dL [29 g/L] [reference range, 3.7–4.7 g/dL (37–47 g/L)]); and positive immunoglobulin G antibodies for SARS-CoV-2. His electrocardiogram revealed normal sinus rhythm. His echocardiogram was significant for mildly depressed left ventricular systolic function of 23% (reference range, 30%–45%), ejection fraction of 39% (reference range, 50%–80%), and coronary arteries with z scores less than 2, indicating no dilatation. (1)The patient was diagnosed as having MIS-C in the setting of prolonged fever, evidence of multisystem involvement, elevated cardiac and inflammatory markers, and positive SARS-CoV-2 serology. On examination, he had only 2 of the 5 Kawasaki disease features: bilateral conjunctivitis and mucous membrane changes. He also had insufficient supplemental laboratory values to meet the criteria for incomplete Kawasaki disease. Per the institution’s MIS-C guidelines, he was started on methylprednisolone 2 mg/kg per day (70 mg/d) and aspirin 81 mg/d. The next day, his repeated echocardiogram revealed improving left ventricular systolic function to 28% and ejection fraction to 54% but newly developed dilatation of his right and left main coronary arteries with z scores of 2.08 and 2.54, respectively. In response, he received 2 g/kg of intravenous immunoglobulin (IVIg). His follow-up echocardiogram 24 hours after the completion of IVIg showed stable function but worsening dilatation of his right main coronary artery and now his left anterior descending artery. In addition, his cardiac markers had further increased (troponin level, 4.27 ng/mL [4.27 µg/L] [reference range, <0.045 ng/mL (<0.045 µg/L)]; brain natriuretic peptide level, 494 pg/mL [494 ng/L] [reference range, <100.0 pg/mL (<100.0 ng/L)]). His methylprednisolone dose was subsequently increased from 2 mg/kg per day to 4 mg/kg per day (140 mg/d). During this time, he remained afebrile and developed no new physical examination findings. His blood pressure progressively increased while taking high-dose corticosteroids (Fig 1).On hospital day 8, he is found to be unresponsive, with bilateral eye deviation and flaccid posturing. A rapid response is called, and he is given positive pressure ventilation via bag mask for apnea and oxygen desaturations to the 70s. His other vital signs are notable for a heart rate of 86 beats/min and blood pressure of 149/98 mm Hg. He is transferred to the PICU, where he is intubated with sedation for hypoxemia and altered mental status. Noncontrast head computed tomography shows no acute intracranial pathology. Laboratory values are significant for leukocytosis, a stable hemoglobin level, normal electrolyte levels, a normal C-reactive protein level, and venous blood gas with a pH of 7.26, a carbon dioxide level of 74 mEq/L (74 mmol/L), and base excess of 4 mEq/L (4 mmol/L).MIS-C is known to increase the risk of thrombosis; thus, stroke and venous sinus thrombosis were high on the differential diagnosis. His high dose of corticosteroids raised concern for hypertensive encephalopathy and posterior reversible encephalopathy syndrome (PRES). He was also at risk for intracranial hemorrhage while taking aspirin and for aseptic meningitis after receiving IVIg. SARS-CoV-2 encephalopathy and postviral demyelinating disease were thought to be less likely given his acute change in clinical status. Status epilepticus was also considered in the setting of his eye deviation and loss of tone.On transfer to the PICU, the patient was started on a nicardipine drip for sustained hypertension. He received a loading dose of levetiracetam due to the clinical concern for seizure activity. Further evaluation included a continuous electroencephalogram, which was negative for seizure activity. Magnetic resonance imaging (MRI) of the patient’s brain revealed hyperintense cortical and subcortical fluid-attenuated inversion recovery (FLAIR) abnormalities involving the bilateral paramedian parietal lobes (Fig 2). No mass or acute hemorrhage was identified. Magnetic resonance venography was negative for dural venous thrombosis. The patient’s MRI, in concert with his altered mental status and hypertension, was consistent with a diagnosis of PRES. Further evaluation, such as a lumbar puncture, was not indicated after his MRI was found to be diagnostic.PRES presents with acute onset of neurologic symptoms typically in the setting of hypertension and characteristic findings on MRI. This syndrome has been reported in 0.04% of the general pediatric patient population and 0.4% of PICU patients. The mean age at onset of PRES in the pediatric population is 12.5 years. (2)Variable neurologic findings include seizures, altered mental status, headaches, visual disturbances, and focal neurologic deficits. Seizures, typically the generalized tonic-clonic type, are the most common symptom. In addition, hypertension before presentation has been reported in 70% to 80% of pediatric patients who develop PRES. (2) In a retrospective study by Siebert et al, (3) the mean blood pressure in pediatric patients at the onset of PRES was 140/85 mm Hg. It has been suggested that the diagnosis of PRES should be considered when a patient’s blood pressure measures 30% above the 95th percentile for the patient’s given age. (2) According to the clinical practice guideline published by the American Academy of Pediatrics, this equals a blood pressure of 152/98 mm Hg in the patient described. (4)In addition to clinical findings, the identification of PRES can be accomplished with imaging. MRI has been diagnostic for PRES in 98% of cases, compared with only 46% with computed tomography. MRI reveals hyperintensities on T2-weighted and FLAIR imaging in the cortical and subcortical regions of the parietal and occipital lobes. Electroencephalography is also commonly performed because these patients can present with seizures. Results typically demonstrate nonspecific changes indicating encephalopathy. (2)Risk factors for PRES in pediatric patients include but are not limited to hypertension, renal and autoimmune disorders, history of transplant or cancer, and treatment with immunosuppressants, chemotherapy, monoclonal antibodies, and IVIg. The suspected pathogenesis of PRES involves 2 mechanisms of brain edema: vasogenic and cytotoxic. (2) Hypertension, which is seen in most patients with PRES, disrupts the integrity of the blood-brain barrier and increases its permeability, leading to vasogenic edema. The second theory relates to the small percentage of patients who do not present with hypertension. Cytotoxic edema occurs as a result of cellular injury and endothelial dysfunction by certain agents, including immunosuppressants. (2)(5)At the time of the patient’s presentation, the mainstay of treatment for MIS-C was 2 g/kg of IVIg and 1 to 2 mg/kg per day of methylprednisolone with an increase to 4 to 10 mg/kg per day for refractory disease. (6) The patient most likely developed PRES secondary to his treatment with high-dose corticosteroids, which contributed to his hypertension, and IVIg. This case highlights the importance of recognizing and managing elevated blood pressures in patients being treated for MIS-C because they are at risk for developing this severe neurologic complication.Early diagnosis and initiation of treatment of PRES are essential to a favorable prognosis. Patients are managed with supportive care, including antihypertensive medications, antiepileptic medications, airway protection as needed, and close monitoring in the PICU. Patients are at risk for permanent neurologic deficits, and mortality has been reported in 16% of cases. (2)In the PICU, the patient’s blood pressure was controlled with a nicardipine drip and then with as-needed antihypertensive medications. His corticosteroids were continued at a lower dose of approximately 1 mg/kg per day and weaned over 4 weeks. He was also started on a maintenance dose of levetiracetam for seizure prophylaxis. After extubation and weaning his sedation, his physical examination was notable for left hemiparesis. A repeated MRI was negative for stroke but demonstrated resolving cortical and subcortical hyperintensities, indicating improvement in his condition. This left hemiparesis was likely a focal neurologic deficit secondary to PRES.The patient’s course was later complicated by an extensive left lower extremity deep venous thrombosis with secondary bibasilar pulmonary emboli. His family history was negative for venous thromboses and hypercoagulable disorders, including factor V Leiden. His risk factors for thrombosis included hypercoagulability in the setting of MIS-C, immobility due to the focal neurologic deficit affecting his left lower extremity, and May-Thurner anatomy diagnosed by interventional radiology. May-Thurner syndrome increases one’s risk of thrombosis due to compression of the left iliac vein between the right common iliac artery and fifth lumbar vertebrae. He required catheter-directed thrombolysis with interventional radiology and a heparin drip, which was later transitioned to enoxaparin.Before discharge, the patient’s repeated echocardiogram was normal, and his mental status had returned to baseline. His ophthalmic examination results were normal, including full visual fields and bilateral retinae and optic discs without abnormalities. His echocardiogram remained stable at his cardiology follow-up 2 weeks later, and he was able to discontinue levetiracetam at his neurology follow-up 3 months after discharge. His left-sided weakness continues to improve with outpatient physical therapy.The medications used to treat multisystem inflammatory syndrome in children, specifically corticosteroids and intravenous immunoglobulin, increase the risk of posterior reversible encephalopathy syndrome (PRES).Suspect PRES in a patient who presents with hypertension and neurologic symptoms such as altered mental status, seizures, headaches, visual disturbances, and focal neurologic deficits.Brain magnetic resonance imaging should be strongly considered to rule out PRES in these patients.Thank you to the patient and his family for allowing us to present his case to the pediatric community.
No takes yet. Share an insight, caveat, or question.
Himes et al. (2024) conducted a case report in Multisystem inflammatory syndrome in children (MIS-C) and Posterior Reversible Encephalopathy Syndrome (PRES) (n=1). Corticosteroids and Intravenous Immunoglobulin (IVIg) was evaluated. An 8-year-old boy treated with high-dose corticosteroids and intravenous immunoglobulin for MIS-C developed severe hypertension and posterior reversible encephalopathy syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: